Acute myeloid leukemia is a malignant neoplastic disease that usually results from the deterioration of stem cells in the bone marrow. Biomarker detection is a method that can detect specific molecular or genetic variations of leukemia cells, which can be used to diagnose AML, evaluate patient prognosis, and guide the selection of treatment options.
The global market for Acute Myeloid Leukemia Biomarker Detection was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Acute Myeloid Leukemia Biomarker Detection, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Acute Myeloid Leukemia Biomarker Detection by region & country, by Type, and by Application.
The Acute Myeloid Leukemia Biomarker Detection market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acute Myeloid Leukemia Biomarker Detection.
Market Segmentation
By Company
Abbott Laboratories
Bio-Rad Laboratories, Inc.
Genmark Saghlk Orinleri
Laboratory Corporation of America Holdings
Danaher
Medaysis Company
NeoGenomics Laboratories
QIAGEN N.V.
Thermo Fisher Scientific, Inc.
GeneTex
Segment by Type:
Next Generation Sequencing Technology
PCR Detection Technology
Segment by Application
Hospital
Research Institutions
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Acute Myeloid Leukemia Biomarker Detection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Acute Myeloid Leukemia Biomarker Detection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Acute Myeloid Leukemia Biomarker Detection in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Market Overview
1.1 Acute Myeloid Leukemia Biomarker Detection Product Introduction
1.2 Global Acute Myeloid Leukemia Biomarker Detection Market Size Forecast
1.2.1 Global Acute Myeloid Leukemia Biomarker Detection Sales Value (2019-2030)
1.2.2 Global Acute Myeloid Leukemia Biomarker Detection Sales Volume (2019-2030)
1.2.3 Global Acute Myeloid Leukemia Biomarker Detection Sales Price (2019-2030)
1.3 Acute Myeloid Leukemia Biomarker Detection Market Trends & Drivers
1.3.1 Acute Myeloid Leukemia Biomarker Detection Industry Trends
1.3.2 Acute Myeloid Leukemia Biomarker Detection Market Drivers & Opportunity
1.3.3 Acute Myeloid Leukemia Biomarker Detection Market Challenges
1.3.4 Acute Myeloid Leukemia Biomarker Detection Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Acute Myeloid Leukemia Biomarker Detection Players Revenue Ranking (2023)
2.2 Global Acute Myeloid Leukemia Biomarker Detection Revenue by Company (2019-2024)
2.3 Global Acute Myeloid Leukemia Biomarker Detection Players Sales Volume Ranking (2023)
2.4 Global Acute Myeloid Leukemia Biomarker Detection Sales Volume by Company Players (2019-2024)
2.5 Global Acute Myeloid Leukemia Biomarker Detection Average Price by Company (2019-2024)
2.6 Key Manufacturers Acute Myeloid Leukemia Biomarker Detection Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Acute Myeloid Leukemia Biomarker Detection Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Acute Myeloid Leukemia Biomarker Detection
2.9 Acute Myeloid Leukemia Biomarker Detection Market Competitive Analysis
2.9.1 Acute Myeloid Leukemia Biomarker Detection Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Acute Myeloid Leukemia Biomarker Detection Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Acute Myeloid Leukemia Biomarker Detection as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Next Generation Sequencing Technology
3.1.2 PCR Detection Technology
3.2 Global Acute Myeloid Leukemia Biomarker Detection Sales Value by Type
3.2.1 Global Acute Myeloid Leukemia Biomarker Detection Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Acute Myeloid Leukemia Biomarker Detection Sales Value, by Type (2019-2030)
3.2.3 Global Acute Myeloid Leukemia Biomarker Detection Sales Value, by Type (%) (2019-2030)
3.3 Global Acute Myeloid Leukemia Biomarker Detection Sales Volume by Type
3.3.1 Global Acute Myeloid Leukemia Biomarker Detection Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Acute Myeloid Leukemia Biomarker Detection Sales Volume, by Type (2019-2030)
3.3.3 Global Acute Myeloid Leukemia Biomarker Detection Sales Volume, by Type (%) (2019-2030)
3.4 Global Acute Myeloid Leukemia Biomarker Detection Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Research Institutions
4.1.3 Other
4.2 Global Acute Myeloid Leukemia Biomarker Detection Sales Value by Application
4.2.1 Global Acute Myeloid Leukemia Biomarker Detection Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Acute Myeloid Leukemia Biomarker Detection Sales Value, by Application (2019-2030)
4.2.3 Global Acute Myeloid Leukemia Biomarker Detection Sales Value, by Application (%) (2019-2030)
4.3 Global Acute Myeloid Leukemia Biomarker Detection Sales Volume by Application
4.3.1 Global Acute Myeloid Leukemia Biomarker Detection Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Acute Myeloid Leukemia Biomarker Detection Sales Volume, by Application (2019-2030)
4.3.3 Global Acute Myeloid Leukemia Biomarker Detection Sales Volume, by Application (%) (2019-2030)
4.4 Global Acute Myeloid Leukemia Biomarker Detection Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Acute Myeloid Leukemia Biomarker Detection Sales Value by Region
5.1.1 Global Acute Myeloid Leukemia Biomarker Detection Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Acute Myeloid Leukemia Biomarker Detection Sales Value by Region (2019-2024)
5.1.3 Global Acute Myeloid Leukemia Biomarker Detection Sales Value by Region (2025-2030)
5.1.4 Global Acute Myeloid Leukemia Biomarker Detection Sales Value by Region (%), (2019-2030)
5.2 Global Acute Myeloid Leukemia Biomarker Detection Sales Volume by Region
5.2.1 Global Acute Myeloid Leukemia Biomarker Detection Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Acute Myeloid Leukemia Biomarker Detection Sales Volume by Region (2019-2024)
5.2.3 Global Acute Myeloid Leukemia Biomarker Detection Sales Volume by Region (2025-2030)
5.2.4 Global Acute Myeloid Leukemia Biomarker Detection Sales Volume by Region (%), (2019-2030)
5.3 Global Acute Myeloid Leukemia Biomarker Detection Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Acute Myeloid Leukemia Biomarker Detection Sales Value, 2019-2030
5.4.2 North America Acute Myeloid Leukemia Biomarker Detection Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Acute Myeloid Leukemia Biomarker Detection Sales Value, 2019-2030
5.5.2 Europe Acute Myeloid Leukemia Biomarker Detection Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Acute Myeloid Leukemia Biomarker Detection Sales Value, 2019-2030
5.6.2 Asia Pacific Acute Myeloid Leukemia Biomarker Detection Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Acute Myeloid Leukemia Biomarker Detection Sales Value, 2019-2030
5.7.2 South America Acute Myeloid Leukemia Biomarker Detection Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Acute Myeloid Leukemia Biomarker Detection Sales Value, 2019-2030
5.8.2 Middle East & Africa Acute Myeloid Leukemia Biomarker Detection Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Acute Myeloid Leukemia Biomarker Detection Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Acute Myeloid Leukemia Biomarker Detection Sales Value
6.2.1 Key Countries/Regions Acute Myeloid Leukemia Biomarker Detection Sales Value, 2019-2030
6.2.2 Key Countries/Regions Acute Myeloid Leukemia Biomarker Detection Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Acute Myeloid Leukemia Biomarker Detection Sales Value, 2019-2030
6.3.2 United States Acute Myeloid Leukemia Biomarker Detection Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Acute Myeloid Leukemia Biomarker Detection Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Acute Myeloid Leukemia Biomarker Detection Sales Value, 2019-2030
6.4.2 Europe Acute Myeloid Leukemia Biomarker Detection Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Acute Myeloid Leukemia Biomarker Detection Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Acute Myeloid Leukemia Biomarker Detection Sales Value, 2019-2030
6.5.2 China Acute Myeloid Leukemia Biomarker Detection Sales Value by Type (%), 2023 VS 2030
6.5.3 China Acute Myeloid Leukemia Biomarker Detection Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Acute Myeloid Leukemia Biomarker Detection Sales Value, 2019-2030
6.6.2 Japan Acute Myeloid Leukemia Biomarker Detection Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Acute Myeloid Leukemia Biomarker Detection Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Acute Myeloid Leukemia Biomarker Detection Sales Value, 2019-2030
6.7.2 South Korea Acute Myeloid Leukemia Biomarker Detection Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Acute Myeloid Leukemia Biomarker Detection Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Acute Myeloid Leukemia Biomarker Detection Sales Value, 2019-2030
6.8.2 Southeast Asia Acute Myeloid Leukemia Biomarker Detection Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Acute Myeloid Leukemia Biomarker Detection Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Acute Myeloid Leukemia Biomarker Detection Sales Value, 2019-2030
6.9.2 India Acute Myeloid Leukemia Biomarker Detection Sales Value by Type (%), 2023 VS 2030
6.9.3 India Acute Myeloid Leukemia Biomarker Detection Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Abbott Laboratories
7.1.1 Abbott Laboratories Company Information
7.1.2 Abbott Laboratories Introduction and Business Overview
7.1.3 Abbott Laboratories Acute Myeloid Leukemia Biomarker Detection Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Abbott Laboratories Acute Myeloid Leukemia Biomarker Detection Product Offerings
7.1.5 Abbott Laboratories Recent Development
7.2 Bio-Rad Laboratories, Inc.
7.2.1 Bio-Rad Laboratories, Inc. Company Information
7.2.2 Bio-Rad Laboratories, Inc. Introduction and Business Overview
7.2.3 Bio-Rad Laboratories, Inc. Acute Myeloid Leukemia Biomarker Detection Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Bio-Rad Laboratories, Inc. Acute Myeloid Leukemia Biomarker Detection Product Offerings
7.2.5 Bio-Rad Laboratories, Inc. Recent Development
7.3 Genmark Saghlk Orinleri
7.3.1 Genmark Saghlk Orinleri Company Information
7.3.2 Genmark Saghlk Orinleri Introduction and Business Overview
7.3.3 Genmark Saghlk Orinleri Acute Myeloid Leukemia Biomarker Detection Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Genmark Saghlk Orinleri Acute Myeloid Leukemia Biomarker Detection Product Offerings
7.3.5 Genmark Saghlk Orinleri Recent Development
7.4 Laboratory Corporation of America Holdings
7.4.1 Laboratory Corporation of America Holdings Company Information
7.4.2 Laboratory Corporation of America Holdings Introduction and Business Overview
7.4.3 Laboratory Corporation of America Holdings Acute Myeloid Leukemia Biomarker Detection Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Laboratory Corporation of America Holdings Acute Myeloid Leukemia Biomarker Detection Product Offerings
7.4.5 Laboratory Corporation of America Holdings Recent Development
7.5 Danaher
7.5.1 Danaher Company Information
7.5.2 Danaher Introduction and Business Overview
7.5.3 Danaher Acute Myeloid Leukemia Biomarker Detection Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Danaher Acute Myeloid Leukemia Biomarker Detection Product Offerings
7.5.5 Danaher Recent Development
7.6 Medaysis Company
7.6.1 Medaysis Company Company Information
7.6.2 Medaysis Company Introduction and Business Overview
7.6.3 Medaysis Company Acute Myeloid Leukemia Biomarker Detection Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Medaysis Company Acute Myeloid Leukemia Biomarker Detection Product Offerings
7.6.5 Medaysis Company Recent Development
7.7 NeoGenomics Laboratories
7.7.1 NeoGenomics Laboratories Company Information
7.7.2 NeoGenomics Laboratories Introduction and Business Overview
7.7.3 NeoGenomics Laboratories Acute Myeloid Leukemia Biomarker Detection Sales, Revenue and Gross Margin (2019-2024)
7.7.4 NeoGenomics Laboratories Acute Myeloid Leukemia Biomarker Detection Product Offerings
7.7.5 NeoGenomics Laboratories Recent Development
7.8 QIAGEN N.V.
7.8.1 QIAGEN N.V. Company Information
7.8.2 QIAGEN N.V. Introduction and Business Overview
7.8.3 QIAGEN N.V. Acute Myeloid Leukemia Biomarker Detection Sales, Revenue and Gross Margin (2019-2024)
7.8.4 QIAGEN N.V. Acute Myeloid Leukemia Biomarker Detection Product Offerings
7.8.5 QIAGEN N.V. Recent Development
7.9 Thermo Fisher Scientific, Inc.
7.9.1 Thermo Fisher Scientific, Inc. Company Information
7.9.2 Thermo Fisher Scientific, Inc. Introduction and Business Overview
7.9.3 Thermo Fisher Scientific, Inc. Acute Myeloid Leukemia Biomarker Detection Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Thermo Fisher Scientific, Inc. Acute Myeloid Leukemia Biomarker Detection Product Offerings
7.9.5 Thermo Fisher Scientific, Inc. Recent Development
7.10 GeneTex
7.10.1 GeneTex Company Information
7.10.2 GeneTex Introduction and Business Overview
7.10.3 GeneTex Acute Myeloid Leukemia Biomarker Detection Sales, Revenue and Gross Margin (2019-2024)
7.10.4 GeneTex Acute Myeloid Leukemia Biomarker Detection Product Offerings
7.10.5 GeneTex Recent Development
8 Industry Chain Analysis
8.1 Acute Myeloid Leukemia Biomarker Detection Industrial Chain
8.2 Acute Myeloid Leukemia Biomarker Detection Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Acute Myeloid Leukemia Biomarker Detection Sales Model
8.5.2 Sales Channel
8.5.3 Acute Myeloid Leukemia Biomarker Detection Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
Abbott Laboratories
Bio-Rad Laboratories, Inc.
Genmark Saghlk Orinleri
Laboratory Corporation of America Holdings
Danaher
Medaysis Company
NeoGenomics Laboratories
QIAGEN N.V.
Thermo Fisher Scientific, Inc.
GeneTex
*If Applicable.